검색
Beigene Ltd
ONC관심 목록에 추가
315.970USD
-6.110-1.90%
종가 07-31 16:00（ET）시세는 15분 지연됩니다
32.31B시가총액
67.69P/E TTM
자세한 내용은 Beigene Ltd 회사
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Beigene Ltd 정보
종목 코드 ONC
회사 이름BeOne Medicines AG
상장일Mar 02, 2016
CEOOyler (John Victor)
직원 수11000
유형Depository Receipt
회계 연도 종료Mar 02
주소c/o BeOne Medicines I GmbH
도시BASEL
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Switzerland
우편 번호4051
전화41616851900
웹사이트https://beonemedicines.com/
종목 코드 ONC
상장일Mar 02, 2016
CEOOyler (John Victor)
Beigene Ltd의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
11.61K
-41.00%
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Eric E. Hedrick, M.D.
Dr. Eric E. Hedrick, M.D.
Interim Chief Medical Officer, Immuno-Oncology
Interim Chief Medical Officer, Immuno-Oncology
--
--
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
11.61K
-41.00%
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
자주 묻는 질문
Beigene Ltd의 상위 5대 주주는 누구인가요?
Beigene Ltd의 상위 5대 주주는 다음과 같습니다: Dr. Xiaobin Wu, Ph.D.
Beigene Ltd(ONC)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Beigene Ltd의 주식을 보유한 기관은 총 602곳이며, 이들이 보유한 주식의 총 가치는 약 40.42M로 전체 발행 주식의 36.84%를 차지합니다. 이는 2025Q4 대비 1961186.00 증가한 수치입니다.
Beigene Ltd의 최대 수익원은 무엇인가요?
2026Q1 기준, Beigene Ltd의 Product 부문이 가장 높은 매출을 기록했으며, 금액은 1.37B로 전체 매출의 97.35%를 차지했습니다.